GeneDx Holdings (WGS) EBIT (2020 - 2026)

GeneDx Holdings has disclosed EBIT across 7 years of filings, most recently posting -$57.5 million for Q1 2026.

• In Q1 2026, EBIT fell 1162.82% year-over-year to -$57.5 million; the TTM figure through Mar 2026 stood at -$66.0 million (down 367.93% YoY), while the FY2025 annual figure was -$13.1 million, up 43.67% from the prior year.
• EBIT slipped to -$57.5 million in Q1 2026, from -$14.2 million in the prior quarter.
• Over the last five years, EBIT for WGS reached as high as $9.0 million in Q2 2025 and fell as low as -$324.9 million in Q4 2022.
• The 5-year median for EBIT is -$25.6 million (2023), against an average of -$55.4 million.
• Annual changes were most pronounced in 2025 — EBIT surged 184.7% — and 2026, when it slumped 1162.82%.
• A 5-year view of EBIT shows it stood at -$324.9 million in 2022, then soared by 92.11% to -$25.6 million in 2023, then jumped by 134.34% to $8.8 million in 2024, then sank by 261.65% to -$14.2 million in 2025, then plunged by 303.73% to -$57.5 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$57.5 million, -$14.2 million, and -$3.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.